Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determine the Proportion of Patients With Disabling Post Thrombotic Syndrome (Moderate or Severe) in the Long Term Within the Cohort of Patients Who Participated in the Trial CELEST Therapy.

NCT06046807 is registered in ClinicalTrials.gov with Laboratoires Innothera as lead sponsor.

NCT NCT06046807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06046807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determine the Proportion of Patients With Disabling Post Thrombotic Syndrome (Moderate or Severe) in the Long Term Within the Cohort of Patients Who Participated in the Trial CELEST Therapy.
Lead sponsor
Laboratoires Innothera
Phase
Observational
Overall status
Unknown status
Start date
July 24, 2023
Completion date
December 24, 2023
Enrollment
288 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post thrombotic syndrome